Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. [electronic resource]
Producer: 20160704Description: 808-20 p. digitalISSN:- 1941-837X
- Adamantane -- adverse effects
- Body Mass Index
- Cardiovascular Diseases -- economics
- China
- Computer Simulation
- Cost-Benefit Analysis
- Diabetes Mellitus, Type 2 -- complications
- Dipeptides -- adverse effects
- Dipeptidyl-Peptidase IV Inhibitors -- adverse effects
- Disease Progression
- Drug Therapy, Combination
- Female
- Hospital Costs -- statistics & numerical data
- Humans
- Hypoglycemia -- chemically induced
- Hypoglycemic Agents -- adverse effects
- Insurance Claim Review -- economics
- Kidney Diseases -- economics
- Male
- Metformin -- adverse effects
- Middle Aged
- Models, Economic
- Quality-Adjusted Life Years
- Sulfonylurea Compounds -- adverse effects
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.